{
    "clinical_study": {
        "@rank": "158267", 
        "acronym": "FIT-2", 
        "arm_group": [
            {
                "arm_group_label": "Arm A : TDF + FTC (or 3TC) + ZDV", 
                "arm_group_type": "Experimental", 
                "description": "Tenofovir + Emtricitabine or Lamivudine + Zidovudine"
            }, 
            {
                "arm_group_label": "TDF+FTC (or 3TC) +LPV/r", 
                "arm_group_type": "Experimental", 
                "description": "Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir"
            }, 
            {
                "arm_group_label": "Arm C : TDF +FTC (or 3TC) + RAL", 
                "arm_group_type": "Experimental", 
                "description": "Tenofovir + Emtricitabine or Lamivudine + Raltegravir"
            }
        ], 
        "brief_summary": {
            "textblock": "FIT-2 is a multi-country, phase IIb, randomized, non-comparative study, carried out in West\n      Africa (C\u00f4te d'Ivoire, Burkina Faso, Senegal, Togo, Guinea).\n\n      ARV-na\u00efve HIV-2 infected adult patients will be recruited and followed during 96 weeks.\n\n      The objective is to evaluate the efficacy and safety of 3 first-line treatments in HIV-2\n      infected adult patients, in West Africa. A treatment will be considered as effective if more\n      than 55% of patients in that arm attain \"global success\" at 96 weeks."
        }, 
        "brief_title": "First-Line Treatment for HIV-2", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-2 Infection", 
        "condition_browse": {
            "mesh_term": "HIV Infections"
        }, 
        "detailed_description": {
            "textblock": "Main objective\n\n      To determine in treatment-na\u00efve HIV-2 infected patients, with CD4 counts between 200 and 600\n      cells/mm3  or with HIV-2 RNA viral loads >50copies/ml and CD4 counts above 200 cells/mm3,\n      which of the following three regimens of first line treatment, Tenofovir (TDF),\n      Emtricitabine or lamivudine (FTC or 3TC) plus Zidovudine (ZDV); TDF-FTC (3TC) plus\n      Lopinavir/ritonavir (LPV / r); or TDF-FTC (3TC) plus raltegravir (RAL), will result in an\n      \"global success\" rate of > 55% at week 96.\n\n      Number of participants : 210\n\n      Main outcome :\n\n      The proportion of patients with \"global success\" at W96, defined by survival with a plasma\n      HIV-2 RNA viral load of \u226450 copies/ml and the non-occurrence of AIDS classified events\n      (excluding tuberculosis) and a delta of CD4 depending on the initial CD4 count (CD4 delta>\n      +100cells/mm3 for initial CD4s between 201 and 500 cells/mm3 or delta> 50 cells/mm3 for\n      initial CD4s > +500 cells/mm3)\n\n      Inclusion criteria:\n\n        -  Infection by HIV-2 only;\n\n        -  Age > or = 18 years;\n\n        -  Na\u00efve for antiretroviral therapy (including antiretroviral treatment in the context of\n           PMTCT)\n\n        -  CD4 >200/mm3 and \u2264600/mm3 irrespective of plasma HIV-2 RNA viral load, OR HIV-2 RNA\n           viral load plasma > 50 copies/ml if the CD4 count is >200 cells/mm3\n\n        -  Resident of the city where the study is held or of city suburbs to facilitate\n           participation\n\n        -  Signed informed consent"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Infection by HIV-2 only;\n\n          -  Age > 18 years;\n\n          -  Na\u00efve for antiretroviral therapy (including antiretroviral treatment in the context\n             of PMTCT)\n\n          -  CD4 >200/mm3 and \u2264600/mm3 irrespective of plasma HIV-2 RNA viral load, OR HIV-2 RNA\n             viral load plasma > 50 copies/ml if the CD4 count is >200 cells/mm3\n\n          -  Resident of the city where the study is held or of city suburbs to facilitate\n             participation\n\n          -  Signed informed consent document\n\n        Exclusion Criteria:\n\n          -  Current participation in any other clinical trial\n\n          -  Presence of opportunistic non-stabilized infections, of any serious or progressive\n             disease, or of any clinical signs consistent with severe disease whose diagnosis is\n             not yet confirmed, such as fever, weight loss, diarrhea or cough not yet explained\n             (non-exhaustive list).\n\n          -  All pathology that leads in daily life to prefer one or the other of the three\n             therapeutic regimens for medical reasons or to change the dosages specified in the\n             test. This includes (but not limited to):\n\n          -  Hemoglobin \u2264 8 g / L\n\n          -  Neutrophil count <500 cells/mm3\n\n          -  Renal impairment with creatinine clearance <50mL/mn\n\n          -  Decompensated heart failure\n\n          -  Hepatic failure Severe (TP<50% or cytolysis severe (ALAT> 3x ULN)\n\n          -  Active TB during treatment with rifampicin\n\n          -  Taking drugs that interact with the drugs of the clinical trial  (as specified in the\n             SPC)\n\n          -  Pregnancy, breastfeeding or planning to become pregnant during study follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150993", 
            "org_study_id": "ANRS 12294 FIT-2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A : TDF + FTC (or 3TC) + ZDV", 
                "description": "TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)", 
                "intervention_name": "Tenofovir + Emtricitabine or Lamivudine + Zidovudine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TDF+FTC (or 3TC) + ZDV", 
                    "TDF+FTC (or 3TC) + AZT"
                ]
            }, 
            {
                "arm_group_label": "TDF+FTC (or 3TC) +LPV/r", 
                "description": "TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)", 
                "intervention_name": "Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir", 
                "intervention_type": "Drug", 
                "other_name": "TDF +FTC (or 3TC) +LPV/r"
            }, 
            {
                "arm_group_label": "Arm C : TDF +FTC (or 3TC) + RAL", 
                "description": "TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)", 
                "intervention_name": "Tenofovir + Emtricitabine or Lamivudine + Raltegravir", 
                "intervention_type": "Drug", 
                "other_name": "TDF +FTC (or 3TC) + RAL"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Lamivudine, zidovudine drug combination", 
                "Ritonavir", 
                "Lopinavir", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Africa", 
            "Antiretroviral Treatment", 
            "HIV-2", 
            "firsts line ART", 
            "Adults"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "link": [
            {
                "description": "sponsor site", 
                "url": "http://www.anrs.fr"
            }, 
            {
                "description": "Related Info", 
                "url": "http://www.mereva.net/"
            }
        ], 
        "location": [
            {
                "contact": {
                    "email": "sawadogoadrien@yahoo.fr", 
                    "last_name": "Adrien B Sawadogo, MD", 
                    "phone": "+22620985255"
                }, 
                "contact_backup": {
                    "email": "zojacques@yahoo.fr", 
                    "last_name": "Jacques Zougrana, MD", 
                    "phone": "+22620983758"
                }, 
                "facility": {
                    "address": {
                        "city": "Bobo-Dioulasso", 
                        "country": "Burkina Faso"
                    }, 
                    "name": "CHU Sour\u00f4 Sanou"
                }, 
                "investigator": {
                    "last_name": "Jacques Zoungrana, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "yjdrabo@yahoo.fr", 
                    "last_name": "Youssef Joseph Drabo, Pr. MD", 
                    "phone": "+22650311656"
                }, 
                "contact_backup": {
                    "email": "illah_diallo@hotmail.com", 
                    "last_name": "Ismael Diallo, MD", 
                    "phone": "+22670249814"
                }, 
                "facility": {
                    "address": {
                        "city": "Ouagadougou", 
                        "country": "Burkina Faso"
                    }, 
                    "name": "CHU Yalgado Ouedraogo"
                }, 
                "investigator": {
                    "last_name": "Isamel Diallo, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "messou_eugene@yahoo.fr", 
                    "last_name": "Eug\u00e8ne Messou, MD, PhD", 
                    "phone": "+22523462551"
                }, 
                "contact_backup": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Centre de Prise en Charge et de Formation (CePReF), Association ACONDA"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "minga.albert@yahoo.fr", 
                    "last_name": "Albert Kla Minga, MD, PhD", 
                    "phone": "+225 21 35 52 78"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Centre M\u00e9dical du Suivi des Donneurs de Sang (Blood Bank Medical Centre)"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "bissagnene@yahoo.fr", 
                    "last_name": "Emmanuel Bissagnene, MD, Pr", 
                    "phone": "+22521755960"
                }, 
                "contact_backup": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "Service des Maladies Infectieuses et Tropicales (SMIT)"
                }, 
                "investigator": {
                    "last_name": "Eboumou Gole, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "chenalhenri@gmail.com", 
                    "last_name": "Henry Chenal, MD"
                }, 
                "contact_backup": {
                    "email": "hawer_d@yahoo.fr", 
                    "last_name": "Denise Hawerlander, MD", 
                    "phone": "+225 07 67 25 59"
                }, 
                "facility": {
                    "address": {
                        "city": "Abidjan", 
                        "country": "C\u00f4te D'Ivoire"
                    }, 
                    "name": "CIRBA"
                }, 
                "investigator": {
                    "last_name": "Denise Hawerlander, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "seydi_moussa@gmail.com", 
                    "last_name": "Moussa Seydi, MD, Pr", 
                    "phone": "+221338231327"
                }, 
                "contact_backup": {
                    "email": "nogayegaye@hotmail.com", 
                    "last_name": "Nogaye Gaye", 
                    "phone": "+221338698193"
                }, 
                "facility": {
                    "address": {
                        "city": "Dakar", 
                        "country": "Senegal"
                    }, 
                    "name": "CHNU Fann"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "noelmagloiremanga@yahoo.fr", 
                    "last_name": "No\u00ebl Magloire Manga, MD", 
                    "phone": "+221338647553"
                }, 
                "facility": {
                    "address": {
                        "city": "Ziguinchor", 
                        "country": "Senegal"
                    }, 
                    "name": "Hopital du district de Ziguinchor"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "patassi40@yahoo.fr", 
                    "last_name": "Patassi Akouda, MD", 
                    "phone": "+228 90 98 17 74"
                }, 
                "facility": {
                    "address": {
                        "city": "Lom\u00e9", 
                        "country": "Togo"
                    }, 
                    "name": "CHU Sylvanus-Olympio"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Burkina Faso", 
                "C\u00f4te D'Ivoire", 
                "Senegal", 
                "Togo"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-na\u00efve HIV-2 Infected Adult Patients, in West Africa", 
        "overall_contact": {
            "email": "geraldine.colin11@gmail.com", 
            "last_name": "G\u00e9raldine Colin, DPharm", 
            "phone": "+22521755960"
        }, 
        "overall_contact_backup": {
            "email": "Xavier.Anglaret@isped.u-bordeaux2.fr", 
            "last_name": "Xavier Anglaret, MD, PHD", 
            "phone": "+22521755960"
        }, 
        "overall_official": [
            {
                "affiliation": "Service des Maladies Infectieuses et Tropicales,  CHU de Treichville, Abidjan, C\u00f4te d'Ivoire", 
                "last_name": "Serge P. Eholi\u00e9, MD, MSc, Pr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Laboratoire de virologie, H\u00f4pital Bichat-Claude Bernard", 
                "last_name": "Fran\u00e7oise P. Brun-V\u00e9zinet, MD, MSc, Pr", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Burkina Faso: Ministry of Health", 
                "Burkina Faso: Minist\u00e8re de la Recherche Scientifique et de l'Innovation", 
                "Burkina Faso: Comit\u00e9 d'Ethique pour la Recherche en Sant\u00e9", 
                "Cote d'Ivoire: Minist\u00e8re de la Sant\u00e9 et de la Lutte contre le SIDA", 
                "Cote d'Ivoire: Comit\u00e9 National d'Ethique et de la Recherche", 
                "Senegal: Ministere de la Sante et de l'Action Sociale", 
                "Senegal: Comit\u00e9 National d'Ethique pour la Recherche en Sant\u00e9", 
                "Guinee Conakry:  Minist\u00e8re de la Sant\u00e9 et de l'Hygi\u00e8ne Publique (MSHP)", 
                "Guinee Conakry: Comit\u00e9 national d'\u00e9thique pour la recherche en sant\u00e9 (CNERS)", 
                "Togo : Comit\u00e9 de bio\u00e9thique pour la recherche en sant\u00e9 ( CBRS)", 
                "Togo : minist\u00e8re de la sant\u00e9"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The proportion of patients with \"global success\" at W96, defined by survival with a plasma HIV-2 RNA viral load of \u226450 copies/ml and the non-occurrence of AIDS classified events (excluding tuberculosis) and a delta of CD4 depending on the initial CD4 count (CD4 delta> +100cells/mm3 for initial CD4s between 201 and 500 cells/mm3 or delta> 50 cells/mm3 for initial CD4s > +500 cells/mm3)\nA treatment is considered to be effective if the \"global success\" is > 55 % at 96 weeks.", 
            "measure": "The \"overall success\"", 
            "safety_issue": "No", 
            "time_frame": "96 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150993"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The percentage of patients in \"treatment failure\" defined by :\ndeath or\na delta CD4 \u22640 cells/mm3 or\na plasma HIV-2 RNA viral load of >50 copies/ml or\nthe occurrence of an AIDS defining event (excluding tuberculosis).", 
                "measure": "Therapeutic failure", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "description": "The percentage of patients in \"treatment failure\" defined by :\ndeath or\na delta CD4 \u22640 cells/mm3 between  or\na plasma HIV-2 RNA viral load of >50 copies/ml or\nthe occurrence of an AIDS defining event (excluding tuberculosis).", 
                "measure": "Therapeutic failure", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "measure": "Incidence and type of severe clinical or biological severe adverse events (grade 3 or 4 on the ANRS grading table) per arm", 
                "safety_issue": "Yes", 
                "time_frame": "between Week 0 and Week 96"
            }, 
            {
                "description": "The incidence of severe morbidity, defined as: AIDS morbidity, non-AIDS cancer, severe non-AIDS bacterial disease, or any disease leading to death", 
                "measure": "The clinical progression", 
                "safety_issue": "Yes", 
                "time_frame": "between Week 0 and Week 96"
            }, 
            {
                "description": "Evolution of the absolute and percentage CD4 counts during follow-up", 
                "measure": "The evolution of CD4 counts", 
                "safety_issue": "No", 
                "time_frame": "between Week 0 and Week 96"
            }, 
            {
                "description": "Evolution of the plasma viral load during follow-up", 
                "measure": "The evolution of plasma HIV-2 RNA load", 
                "safety_issue": "No", 
                "time_frame": "between at W0 and W96"
            }, 
            {
                "description": "To describe the antiretroviral possession ratio and assessment of compliance by questionnaire", 
                "measure": "The observance of antiretroviral treatment", 
                "safety_issue": "No", 
                "time_frame": "between W0 and W96"
            }, 
            {
                "description": "Description of new resistance mutations profiles in cases of treatment failure", 
                "measure": "The resistance mutations profile", 
                "safety_issue": "No", 
                "time_frame": "Weeks 96"
            }, 
            {
                "description": "To describe the evolution the HIV-2 DNA titers in PBMC", 
                "measure": "The evolution of the HIV-2 DNA titers in PBMC", 
                "safety_issue": "No", 
                "time_frame": "between Week 0 and Week 96"
            }, 
            {
                "description": "The frequency of modifications and discontinuations of treatment per arm", 
                "measure": "The frequency of treatment switches and discontinuations", 
                "safety_issue": "No", 
                "time_frame": "between Week 0 and Week 96"
            }, 
            {
                "description": "The probability of survival and the incremental cost-effectiveness of these three treatment regimens", 
                "measure": "To model the long-term survival and cost-effectiveness ratio", 
                "safety_issue": "No", 
                "time_frame": "Weeks 96"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}